CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
about
Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?Chimeric antigen receptor T‑cell therapy—a hematological success story.Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell TherapyCAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell GrowthImmune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T CellsOncolytic Viruses Partner With T-Cell Therapy for Solid Tumor TreatmentCD22: A Regulator of Innate and Adaptive B Cell Responses and AutoimmunityCAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor ChallengeCD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulumThe biological basis and clinical symptoms of CAR-T therapy-associated toxicitesThe potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALLCAR T Cell Therapy for Neuroblastoma
P2860
Q48168880-0CB6AC2C-2A51-4508-A913-6530750F0FBEQ49878390-01BBBBB7-C237-408E-B289-7888F1DA6479Q55292778-6AF2AF2B-355A-4655-AEF7-39B643075BF9Q55443158-D9CE821D-11EA-4051-B9A0-FD6F85A0D371Q56333808-2CE4A16E-5CB8-49F3-9747-F09AA62A308BQ57158297-3D21DEAF-BC76-4E7A-BA78-4A83C7BA3099Q57173949-90EE8E23-F191-46D7-8B61-FE1446C1360BQ57300017-D834696F-5E3C-4C1C-A4AC-5DEB217D5E0EQ57490095-51A85E62-10F5-4C39-9247-5FA76C01C781Q58572502-EE9C7789-A019-4FF2-9575-43AD546A05EAQ58736815-52F62ADA-CAC5-4FE4-952E-B510956EE9B0Q58765358-1010A9B5-1281-4399-AC1D-59FC1EED9C75Q58767159-B7669B56-C351-46FF-9954-22F4B8238467Q59127901-2E9140C0-79A0-42B6-A62B-56C539C4CF70
P2860
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
CD22-targeted CAR T cells indu ...... 19-targeted CAR immunotherapy.
@en
CD22-targeted CAR T cells indu ...... 19-targeted CAR immunotherapy.
@nl
type
label
CD22-targeted CAR T cells indu ...... 19-targeted CAR immunotherapy.
@en
CD22-targeted CAR T cells indu ...... 19-targeted CAR immunotherapy.
@nl
prefLabel
CD22-targeted CAR T cells indu ...... 19-targeted CAR immunotherapy.
@en
CD22-targeted CAR T cells indu ...... 19-targeted CAR immunotherapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
CD22-targeted CAR T cells indu ...... D19-targeted CAR immunotherapy
@en
P2093
Bonnie Yates
Boro Dropulic
Cindy Delbrook
Constance M Yuan
David F Stroncek
Dimiter S Dimitrov
Haiying Qin
Haneen Shalabi
Jack F Shern
Ling Zhang
P2860
P2888
P356
10.1038/NM.4441
P407
P577
2017-11-20T00:00:00Z